TY - JOUR
T1 - Description of an endometrioid ovarian cancer cell line
AU - Giancotti, Francesca R.
AU - Dorsett, Brent H.
AU - Weaver, Scott C.
AU - Bharathur, Rajendra
AU - Ioachim, Harry L.
AU - Barber, Hugh R.K.
PY - 1989/12
Y1 - 1989/12
N2 - A human cell line, designated L-1, has been established from the ascites of an untreated patient with stage IV (FIGO) endometrioid ovarian cancer. This cell line initially grew uninterrupted for 6 months without fibroblast contamination and contact inhibition, and has been subcultured weekly for the past 7 years. L-1 does not contain steroid hormone receptors nor does it demonstrate the presence of oncofetal antigens by immunohistochemical techniques. The doubling time of L-1 is 11.8 hr. Flow cytometric analysis reveals an aneuploid DNA peak, and an abnormal karyotype demonstrates hyperdiploidy, translocations, and deletions. Morphology, growth patterns, cytogenetic analysis, and other features of L-1 are characterized.
AB - A human cell line, designated L-1, has been established from the ascites of an untreated patient with stage IV (FIGO) endometrioid ovarian cancer. This cell line initially grew uninterrupted for 6 months without fibroblast contamination and contact inhibition, and has been subcultured weekly for the past 7 years. L-1 does not contain steroid hormone receptors nor does it demonstrate the presence of oncofetal antigens by immunohistochemical techniques. The doubling time of L-1 is 11.8 hr. Flow cytometric analysis reveals an aneuploid DNA peak, and an abnormal karyotype demonstrates hyperdiploidy, translocations, and deletions. Morphology, growth patterns, cytogenetic analysis, and other features of L-1 are characterized.
UR - http://www.scopus.com/inward/record.url?scp=0024831944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024831944&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(89)90073-5
DO - 10.1016/0090-8258(89)90073-5
M3 - Article
C2 - 2480932
AN - SCOPUS:0024831944
SN - 0090-8258
VL - 35
SP - 330
EP - 337
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -